Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1/L1 Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05115500
What this trial is testing

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Who this might be right for
CarcinomaSolid Tumor
Second Affiliated Hospital of Soochow University 55
Early research (Phase 1)Looking for participantsNCT07404332
What this trial is testing

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Who this might be right for
Solid TumorLocally Advanced Solid TumorMetastatic Tumor
Mohammed Milhem 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT05599789
What this trial is testing

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Peking Union Medical College Hospital 47
Early research (Phase 1)Active Not RecruitingNCT05354323
What this trial is testing

NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

Who this might be right for
Solid Tumors, Adult
NEC OncoImmunity AS 6
Large-scale testing (Phase 3)UnknownNCT05322187
What this trial is testing

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy

Who this might be right for
Transitional Cell TumorHepatoblastomaLiver Cancer+2 more
RenJi Hospital 15
Not applicableUnknownNCT06402981
What this trial is testing

A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients

Who this might be right for
Immune Checkpoint InhibitorsLiver Injury
Zhejiang University 2,000
Testing effectiveness (Phase 2)Looking for participantsNCT06657690
What this trial is testing

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Who this might be right for
Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University 56
Testing effectiveness (Phase 2)Study completedNCT03083808
What this trial is testing

Phase II Trial of Continuation Therapy in Advanced NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Greg Durm, MD 35
Testing effectiveness (Phase 2)UnknownNCT04313660
What this trial is testing

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Who this might be right for
NSCLCAnlotinibPD-1/L1 Inhibitor
Xiaorong Dong 33
Not applicableActive Not RecruitingNCT05364086
What this trial is testing

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Who this might be right for
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
University of Rochester NCORP Research Base 2,100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03228667
What this trial is testing

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Who this might be right for
Non-Small Cell Lung CancerSmall Cell Lung CancerUrothelial Carcinoma+10 more
ImmunityBio, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT04121442
What this trial is testing

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Who this might be right for
Solid Tumor, Adult
Buzzard Pharmaceuticals 15
Not applicableLooking for participantsNCT07829081
What this trial is testing

Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors

Who this might be right for
Quality of Life (QOL)Mismatch Repair Deficient Colorectal CancerMicrosatellite Instability-High Colorectal Cancer+8 more
University Hospital, Basel, Switzerland 234
Testing effectiveness (Phase 2)Looking for participantsNCT06463665
What this trial is testing

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Who this might be right for
Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaMetastatic Non-squamous Non Small Cell Lung Cancer+5 more
Genelux Corporation 142
Early research (Phase 1)Active Not RecruitingNCT04387084
What this trial is testing

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Who this might be right for
Advanced Malignant Skin NeoplasmMetastatic Malignant Skin Neoplasm
University of Southern California 10
Not applicableLooking for participantsNCT05713994
What this trial is testing

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06925048
What this trial is testing

SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

Who this might be right for
Non-Small Cell Lung CancerJAK InhibitorImmunology
Chunxia Su 86
Not applicableUnknownNCT05717738
What this trial is testing

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Tongji Hospital 300
Early research (Phase 1)Study completedNCT03340766
What this trial is testing

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Amgen 31
Large-scale testing (Phase 3)WithdrawnNCT06513884
What this trial is testing

HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Who this might be right for
Oropharyngeal Squamous Cell Carcinoma Recurrent
Hookipa Biotech GmbH
Next Page